CO2019011359A2 - Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii - Google Patents

Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii

Info

Publication number
CO2019011359A2
CO2019011359A2 CO2019011359A CO2019011359A CO2019011359A2 CO 2019011359 A2 CO2019011359 A2 CO 2019011359A2 CO 2019011359 A CO2019011359 A CO 2019011359A CO 2019011359 A CO2019011359 A CO 2019011359A CO 2019011359 A2 CO2019011359 A2 CO 2019011359A2
Authority
CO
Colombia
Prior art keywords
prognosis
gastric cancer
predicting
patients
benefit
Prior art date
Application number
CO2019011359A
Other languages
English (en)
Inventor
Jae Ho Cheong
Sung Hoon Noh
Yong Min Huh
Hyun Ki Kim
Original Assignee
Novomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomics Co Ltd filed Critical Novomics Co Ltd
Publication of CO2019011359A2 publication Critical patent/CO2019011359A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio II y III, y se desarrolla un algoritmo que puede predecir el pronóstico y la respuesta a quimioterapia usando resultados de análisis cuantitativo de niveles de expresión de ARNm de un grupo de genes marcadores relacionados con el pronóstico o la respuesta a quimioterapia y un grupo de genes de referencia en cáncer gástrico avanzado, y puede usarse como información complementaria para determinar un método para tratar a un paciente con cáncer gástrico.
CO2019011359A 2017-03-14 2019-10-15 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii CO2019011359A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170032027 2017-03-14
PCT/KR2017/008781 WO2018169145A1 (ko) 2017-03-14 2017-08-11 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템

Publications (1)

Publication Number Publication Date
CO2019011359A2 true CO2019011359A2 (es) 2019-10-31

Family

ID=63523198

Family Applications (1)

Application Number Title Priority Date Filing Date
CO2019011359A CO2019011359A2 (es) 2017-03-14 2019-10-15 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii

Country Status (17)

Country Link
US (1) US11732304B2 (es)
EP (1) EP3517624A4 (es)
JP (1) JP6864089B2 (es)
KR (2) KR101966642B1 (es)
CN (1) CN110168106B (es)
AU (1) AU2017403899B2 (es)
BR (1) BR112019019022A2 (es)
CA (1) CA3055735C (es)
CL (1) CL2019002633A1 (es)
CO (1) CO2019011359A2 (es)
IL (1) IL269256A (es)
MX (1) MX2019011017A (es)
NZ (1) NZ756580A (es)
PE (1) PE20191482A1 (es)
RU (1) RU2737449C1 (es)
UA (1) UA125590C2 (es)
WO (1) WO2018169145A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017403899B2 (en) 2017-03-14 2021-12-09 Novomics Co., Ltd. System for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage ii and iii gastric cancer
US20220267855A1 (en) * 2019-05-03 2022-08-25 Dcgen Co, Ltd. A Method for Predicting Prognosis of Cancer and the Composition Thereof
KR102324294B1 (ko) * 2019-11-19 2021-11-11 서울대학교산학협력단 상피성 난소암 예후 예측 방법 및 장치
KR20220069869A (ko) 2020-11-20 2022-05-27 연세대학교 산학협력단 간암의 예후 예측을 위한 정보 제공 방법
KR102462097B1 (ko) * 2020-12-30 2022-11-02 국립암센터 삼중사중극자 다중반응 모니터링 기반 암 표적치료제 효능 예측
CN113462773A (zh) * 2021-05-19 2021-10-01 山东大学 一种预测胃癌患者生存风险、免疫治疗响应和细胞焦亡诱导剂适用性的标志物及其应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
WO2005007846A1 (ja) 2003-04-25 2005-01-27 Japanese Foundation For Cancer Research 腫瘍細胞の抗癌剤に対する感受性を判定する方法
KR20080006315A (ko) * 2006-07-12 2008-01-16 삼성전자주식회사 전기 영동 장치 및 그의 제조 방법
ES2814027T3 (es) 2006-12-27 2021-03-25 Abion Inc Procedimiento de procesamiento y análisis de datos de expresión génica para identificar genes de referencia endógenos
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
WO2012081898A2 (ko) 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
KR101504817B1 (ko) * 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
MX2017005751A (es) * 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
AU2017403899B2 (en) 2017-03-14 2021-12-09 Novomics Co., Ltd. System for predicting prognosis and benefit from adjuvant chemotherapy for patients with stage ii and iii gastric cancer

Also Published As

Publication number Publication date
AU2017403899B2 (en) 2021-12-09
PE20191482A1 (es) 2019-10-18
NZ756580A (en) 2022-01-28
US11732304B2 (en) 2023-08-22
EP3517624A4 (en) 2020-04-29
KR101966642B1 (ko) 2019-04-09
UA125590C2 (uk) 2022-04-27
US20190284637A1 (en) 2019-09-19
CN110168106B (zh) 2024-02-20
BR112019019022A2 (pt) 2020-04-22
IL269256A (en) 2019-11-28
JP6864089B2 (ja) 2021-04-21
CN110168106A (zh) 2019-08-23
KR102069043B1 (ko) 2020-01-22
CA3055735C (en) 2021-12-14
KR20180105036A (ko) 2018-09-27
AU2017403899A1 (en) 2019-09-19
EP3517624A1 (en) 2019-07-31
MX2019011017A (es) 2020-01-20
RU2737449C1 (ru) 2020-11-30
CL2019002633A1 (es) 2020-04-03
KR20190024923A (ko) 2019-03-08
WO2018169145A1 (ko) 2018-09-20
JP2019537436A (ja) 2019-12-26
CA3055735A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
CO2019011359A2 (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii
CL2020001730A1 (es) Método para el tratamiento de cáncer. (divisional solicitud 201702728)
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
BR112015030627A2 (pt) marcadores biológicos úteis na imunoterapia contra o câncer
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
JOP20190199B1 (ar) استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
BR112018008799A2 (pt) método de prognóstico
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
BR112017012287A2 (pt) uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr
MA40636A (fr) Procédés pour détecter le cancer de la prostate
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112016015595A2 (pt) métodos de determinação de câncer de pulmão
BR112016023822A2 (pt) ?método e composição de inibição de corrosão?
BR112017016014A2 (pt) método para tratar uma formação subterrânea, sistema para realizar o método para tratar uma formação subterrânea, sistema, composição para o tratamento de uma formação subterrânea, composição de fluido de perfuração para o tratamento de uma formação subterrânea e método para preparar uma composição para o tratamento de uma formação subterrânea
CO2018011200A2 (es) Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer